DGAP-News: Novavax Announces Extension of Contract for

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 27, 2014 at 4:30 PM

DGAP-News: Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA

DGAP-News: Novavax, Inc. / Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA 27.02.2014 / 22:15 --------------------------------------------------------------------- GAITHERSBURG, Md., 2014-02-27 22:15 CET (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the execution of a contract modification to extend the base period of performance of its current contract with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of Novavax' recombinant seasonal and pandemic influenza vaccines. The contract was originally awarded in February 2011, with funding of up to $97 million over an initial base period ending in February 2014. Novavax and BARDA have agreed to amend the agreement to allow Novavax to continue to access the remainder of the $97 million in base period funding through September 2014. These funds will support the upcoming Phase 2 trial for our H7N9 vaccine candidate with Matrix-M, and activities relating to our quadrivalent seasonal influenza vaccine. BARDA has the ability to dedicate up to $79 million in additional funds to support Novavax' later-stage development of these vaccines, during an option period currently anticipated to add two years to the overall performance period. 'Development of our seasonal and pandemic influenza products during the last three years under our contract with BARDA has allowed us to refine and develop influenza vaccine products while delivering important clinical trial results from our seasonal quadrivalent, avian H5N1, and most recently, avian H7N9 studies. While our original development plans anticipated utilizing the full amount of the contracted base-period funding within the three-year period, certain scope changes and development efforts resulted in delayed development timelines. Extending the base period allows us to continue to access the remaining base period budget as we initiate a pandemic H7N9 Phase 2 study early this year and prepare for additional Phase 2 and Phase 3 influenza clinical trials, which we expect would occur during the contract's option period,' said Stanley C. Erck, the company's CEO and President. About the Novavax BARDA Contract In February 2011, Novavax was awarded a contract valued at up to $179 million by BARDA for the advanced development of recombinant influenza vaccine products and manufacturing capabilities for pandemic preparedness. Throughout the contract's base period, Novavax has been developing and testing its novel recombinant virus-like particle (VLP) influenza vaccines to address BARDA's commitment to advancing recombinant-based technology as a component of pandemic preparedness. Upon satisfaction of established milestones, the contract is expected to be extended, upon execution by BARDA of an Option One period. The milestones under the Option One period would focus on completion of the pathway to product licensures from the U.S. Food and Drug Administration (FDA), including support for manufacturing scale-up. There is an additional contract option for vaccine production ($3 million). About Novavax Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Additional information about Novavax is available on the company's website, novavax.com. Forward-Looking Statements Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading 'Risk Factors' in the Novavax Annual Report on Form 10-K for the year ended December 31, 2012, and Form 10-Q for the period ended September 30, 2013, both filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. CONTACT: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 27.02.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Novavax, Inc. United States ISIN: US6700021040 End of News DGAP News-Service --------------------------------------------------------------------- 254916 27.02.2014

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

iTLC Traffic Systems Expand Global Reach at APTA 2026

APTA 2026: The Launchpad for Intelligent Traffic Control Forget the days of manual traffic chaos—by the sounds of it, smart intersections are ready to rule the roads. Today's chatter at APTA 2026 in Chicago was a whirlwind of ideas, all centered around how ICP DAS and Towards Buddha Co., Ltd. plan to shake up traffic management globally with their iTLC Intelligent...

NPKI Faces Legal Scrutiny After Financial Setback

Stockholders Left Scrambling You ever have one of those days where everything is cruising along, then bam—you hit what feels like a pothole the size of Texas? Well, that's NPK International (NYSE: NPKI) right now. Their recent revenue cut sent shareholders spiraling, and now there's a legal storm brewing, led by Levi & Korsinsky. Weather Woes Lead to Lower Earnings So,...

PG&E's $500K Grants Wrap Up Five-Year Environmental Push

Wrapping Up a Half-Decay of Environmental Commitment PG&E has been playing the long game with its environmental initiatives, and this wraps up a five-year saga that's worth dissecting. The PG&E Corporation Foundation has doled out its final set of grants, making a 25-strong lineup of eco-friendly campaigns. We're talking $500,000 split among five organizations trying to...

Reddit's Stock Plunge Sparks Legal Scrutiny

By Ryan Hughes Updated Oct 30, 2026 Category News Views 199

Reddit's Big Gamble: A Risky Shift Investors, grab your coffee, because Reddit (NYSE: RDDT) just gave us a real eyebrow-raiser, and no one's got a clue how deep this rabbit hole goes. They pulled the curtains back and went for a logged-in-only format, and the stock took a nosedive—a good 28% drop, just like that. If you've got a vested interest here, this is your cue to...

WesternU's Big Night: Boosting Lebanon’s Health Hub

Building Bridges in Healthcare: WesternU's Strategic Move Heck, you know it's the real deal when a university throws a dinner party to celebrate partnerships. Western University of Health Sciences (WesternU) decided to clink glasses with Lebanon community leaders, hammering home the importance of their collaboration on October 6, 2026. Now, don't think this was just some...

Glance's Guide Bridges AI and Human Service Gaps

Untangling the AI to Human Transition Ever found yourself stuck in a never-ending loop with AI, screaming for a human voice? You're not alone. According to Glance's 2026 Customer Experience Trends Report, a staggering 76% of consumers are pulling their hair out while repeating themselves when switching service channels. The rub? Only 7% claim they rarely experience this...

Purina's Docuseries Wins Big at Daytime Emmys

Unleashing a Winning Streak Forget stock price fluctuations—Purina Films has struck gold. In a world where brand stories often fall flat or feel contrived, Purina's 'A Different Breed' docuseries just bagged three Daytime Emmy® Awards. It's not every day you see corporate storytelling make a splash like this, but when you blend pets and riveting narratives, magic...

ScienceOra Unveils AI Catalyst Design at Tencent Summit

AI in Material Science: Beyond Buzzwords There's a lot of talk out there about AI changing the world, but it's always a different tune when it's put under a microscope. At the 2026 Tencent Global Digital Ecosystem Summit, ScienceOra and Wenge AI showcased an AI-assisted workflow for designing hydrogen-production catalysts. This isn't your average AI cheerleading session,...

Highway Motors Deal Reflects Shifts in Auto Trade

A Family Legacy Transitions in Virginia The trucking world doesn't stop spinning, and Highway Motors, an International dealer rooted deep in Virginia's soil since 1929, knows this intimately. This isn't just a back-of-the-napkin sale; it's a strategic move sweeping through the Interstate 81 corridor, touching Winchester, Harrisonburg, Roanoke, and Leesburg locales. What...

Emirates Wins 2026 Food Waste Award with Biodigester

Award Goes to Emirates for Sustainable Innovations Here's a twist in the waste management narrative: Emirates Flight Catering (EKFC) snagged the Best Food Waste Initiative of the Year 2026 at none other than the Middle East Waste & Recycling Awards. It's no small feat to stand out in an arena that's buzzing with initiatives left and right. So, what's their secret weapon?...